A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers
Published version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature, and drug responsiveness. Although there have been considerable efforts to classify this disease based on high-throughput sequencing techniques, targeted treatments for specific subgroups have been limited. KRAS and BRAF mutations are prevalent genetic alterations in colorectal cancers, and patients with mutations in either of these genes have a worse prognosis and are resistant to anti-EGFR treatments. In this study, we have found that a subgroup of colorectal cancers, defined by having either KRAS or BRAF (KRAS/BRAF) mutations and BCL2L1 (encoding BCL-XL) amplification, can be effectively targeted by simultaneous inhibition of BCL-XL (with ABT-263) and MCL1 (with YM-155). This combination treatment of ABT-263 and YM-155 was shown to have a synergistic effect in vitro as well as in in vivo patient-derived xenograft models. Our data suggest that combined inhibition of BCL-XL and MCL1 provides a promising treatment strategy for this genomically defined colorectal cancer subgroup. Mol Cancer Ther; 16(10); 2178–90. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“However, these anti-EGFR treatments are less effective in patients with KRAS or BRAF mutations (11, 36, 37).”
BackgroundKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Cited by
Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients
Tsai, P.-C., Lee, T.-H., Kuo, K.-C., Su, F.-Y., Lee, T.-L. M., Marostica, E., Ugai, T., Zhao, M., Lau, M. C., Väyrynen, J. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37179-4 · Cited by 136
Minimized combinatorial CRISPR screens identify genetic interactions in autophagy
Diehl, V., Wegner, M., Grumati, P., Husnjak, K., Schaubeck, S., Gubaš, A., Shah, V. J., Polat, I. H., Langschied, F., Prieto‐Garcia, C., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab309 · Cited by 73
Scherr, A., Möck, A., Gdynia, G., Schmitt, N., Heilig, C. E., Korell, F., Rhadakrishnan, P., Hoffmeister‐Wittmann, P., Metzeler, K. H., Schulze‐Osthoff, K., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03092-7 · Cited by 47
Ghaemi, S., Arefian, E., Valojerdi, R. R., Soleimani, M., Moradimotlagh, A., & Jamshidi‐Adegani, F. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109641 · Cited by 35
Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
Carter, R. J., Milani, M., Butterworth, M., Alotibi, A., Harper, N., Yedida, G., Greaves, G., Al-Zebeeby, A., Jorgensen, A., Schache, A. G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2150-8 · Cited by 32
Metadata
- Authors
- Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., Kim, J.-I., Park, H., Lee, W.-S., & Lee, C.
- Affiliations
- Ewha Womans University (KR)
- Seoul National University (KR)
- Gwangju Institute of Science and Technology (KR)
- Gachon University (KR)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 2178-2190
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2625289674
- Cited by
- 24
- References
- 50
- Citations by year
- 2025: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 11 · 2019: 3
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Cancer Institute (P30CA034196)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- colorectal cancer, KRAS mutation, BRAF mutation, Bcl-xL, Mcl-1, navitoclax, combination therapy, apoptosis inhibition, patient-derived xenografts, anti-EGFR resistance, drug synergy
- MeSH terms
- Aged, Aniline Compounds, Animals, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Imidazoles, Mutation, Naphthoquinones, Sulfonamides, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, bcl-X Protein, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0735
- The paper
- Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., Kim, J.-I., Park, H., Lee, W.-S., & Lee, C. (2017). A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.